Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far?
Onuigbo
M A C
MA
College of Medicine, Mayo Clinic, Rochester, MN, USA. onuigbo.macaulay@mayo.edu
D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002908:Chronic Disease; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D018450:Disease Progression; D004359:Drug Therapy, Combination / Q000379:methods; D005919:Glomerular Filtration Rate; D006801:Humans; D007674:Kidney Diseases / Q000517:prevention & control*; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects*; D017211:Treatment Failure
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors